Other
2031
Merck & Co. 2031 increased by 80.0% to $2.70B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 80.0%, from $1.50B to $2.70B. Over 5 years (FY 2020 to FY 2025), 2031 shows an upward trend with a 17.6% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryProfitability
SignalLower is better
VolatilityStable
First reportedQ4 2015
Last reportedQ4 2025Feb 24, 2026
How to read this metric
Lower projected expenses in later years indicate the eventual expiration of amortization schedules for older acquisitions.
Detailed definition
This represents the projected amortization expense for finite-lived intangible assets for the year 2031. It is part of t...
Peer comparison
Standard disclosure for banks with significant historical acquisition activity.
Metric ID:
other_finite_lived_intangible_assets_amortization_expens_5777a7Historical Data
5 periods
| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $1.40B | $1.30B | $1.10B | $1.50B | $2.70B |
| QoQ Change | — | -7.1% | -15.4% | +36.4% | +80.0% |
| YoY Change | — | -7.1% | -15.4% | +36.4% | +80.0% |
Range$1.10B – $2.70B
CAGR+92.9%
Avg YoY Growth+23.5%
Median YoY Growth+14.6%
Current Streak2 quarters growth
2031 at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s 2031?
- Merck & Co. (MRK) reported 2031 of $2.70B in Q4 2025.
- How has Merck & Co.'s 2031 changed year-over-year?
- Merck & Co.'s 2031 increased by 80.0% year-over-year, from $1.50B to $2.70B.
- What is the long-term trend for Merck & Co.'s 2031?
- Over 5 years (2020 to 2025), Merck & Co.'s 2031 has grown at a 17.6% compound annual growth rate (CAGR), from $1.20B to $2.70B.
- What does 2031 mean?
- The expected non-cash expense for acquired intangible assets in the year 2031.